Catalyst Wire Dossier Catalyst Wire Dossier

Siltuximab (Sylvant)

siltuximab · Janssen Biotech, Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Siltuximab (Sylvant), covering 2024-12-06 to 2024-12-06. Get the full timeline:

Most recent: Clinical Trial Update: An Italian Multicenter Retrospective Observational Study to Assess Effectiveness and Safety of Siltuximab for Patients with Castleman's Disease Treated in Italy in a Real-life Context

See pricing